DIAMEDICA THERAPEUTICS INC.
DIAMEDICA THERAPEUTICS INC.
- USD (-)
- 15 min delayed data - NASDAQ Stocks
Open: -
Change: -
Volume: -
Low: -
High: -
High / Low range: -
Type: Stocks
Ticker: DMAC
ISIN: CA25253X2077

DiaMedica Therapeutics to Present at the 16th Annual Craig-Hallum Institutional Investor Conference on May 29, 2019

  • 53

MINNEAPOLIS, May 22, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that it will be participating in the 16th Annual Craig-Hallum Institutional Investor Conference on Wednesday, May 29, 2019, at the Depot Renaissance Minneapolis Hotel in Minneapolis, MN.  Management will be available to participate in one-on-one meetings with investors and attendees can contact their Craig-Hallum representative to arrange a meeting.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neurological disorders. The Company currently has an ongoing phase II study in acute ischemic stroke and a phase Ib study in chronic kidney disease. DiaMedica’s shares are listed on The Nasdaq Capital Market under the trading symbol “DMAC.”

For more information, please visit www.diamedica.com.

Contact:

Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
[email protected]

Paul Papi
Vice President of Business Development
Phone: (617) 899-5941
[email protected]

ti?nf=NzYyNTU5MiMyOTUwMTM5IzIwMDU0MDA=

DiaMedica-Logo.png

GlobeNewsWire
GlobeNewsWire

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases, financial disclosures and multimedia content to media, investors, and consumers worldwide.